Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Commercial Tests for Tuberculosis Have Discordant Results

By LabMedica International staff writers
Posted on 26 Dec 2011
Commercial diagnosis tests show that the majority of positives prove to be false positives in populations with a low prevalence of tuberculosis (TB).

Commercially available tests for latent tuberculosis infection (LTBI) in a diverse population with a low LTBI prevalence in low-prevalence populace may be incompatible. More...


Scientist at the Walter Reed Army Institute (Silver Springs, MD, USA) conducted a cross-sectional study involving 2,017 military recruits at Fort Jackson in South Carolina. The participants were asked to complete a risk factor questionnaire and were checked for TB with the three commercially available tests, consisting of the tuberculin skin test (TST); the interferon gamma release assays (IGRAs), QuantiFERON-TB Gold In-Tube test (QFT-GIT) and the TSPOT TB test (T-Spot). The scientists also conducted the Battey Skin Test (BST) on all participants to assess the impact of nontuberculosis mycobacteria (NTM) reactivity on test discordance.

The results demonstrated that there was no substantial difference between the TST, QFT-GIT (Cellestis Inc.; Valencia, CA, USA) and T-Spot tests (Oxford Immunotec; Abingdon, UK). From 88 positive test results, 68 participants (77%) showed positive to one test, 10 participants (11.4%) showed positive in two tests, and only 10 people (11.4%) were positive to all three tests. The scientists linked Bacille Calmette Guerin vaccination, the tuberculosis prevalence in the country of birth, and Battey skin test reaction size to being TST positive with IGRA negative test discordance.

These results support evidence that false positive TST results can be caused by nontuberculous mycobacteria (NTM) sensitization. Greater quantitative test results and higher TB risk levels were linked to a higher agreement between tests. James Mancuso, MD, Dr. PH, senior author from the Walter Reed Army Institute of Research, explained that: "Our data support a high proportion of false positives with any of these three tests in a low- prevalence population as 77% of our subjects had positive results with only one test. Lower quantitative results were associated with a smaller risk for TB exposure and single positive tests, and lower risk for TB exposure was associated with decreasing test agreement." The study was published on December 8 2011, in the American Journal of Respiratory and Critical Care Medicine.

Related Links:

Walter Reed Army Institute
Cellestis
Oxford Immunotec



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Spinal Fluid Cell Count Control
Spinalscopics
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.